FrancophonIA/ELRC3.0 huggingface dataset:
English: Analyses performed to identify associations between cytokine levels and incidence of CRS or neurologic events showed that higher levels (peak and AUC at 1 month) of IL-15, as well as IL-6, were associated with Grade 3 or higher neurologic adverse reactions and Grade 3 or higher CRS.
Croatian: Analize provedene kako bi se ustanovila povezanost između razina citokina i incidencije CRS-a ili neuroloških događaja pokazale su da su više razine (vršne i AUC u 1. mjesecu) IL-15 kao i IL-6, bile povezane s neurološkim nuspojavama 3. ili višeg stupnja te CRS-om 3. ili višeg stupnja.
English: Patients treated with YESCARTA should not donate blood, organs, tissues, and cells for transplantation.
Croatian: Bolesnici liječeni lijekom YESCARTA ne smiju darivati krv, organe, tkiva i stanice za transplantaciju.
English: Prophylactic anti-microbials should be administered according to standard institutional guidelines.
Croatian: Potrebno je primijeniti profilaktičke antimikrobne lijekove u skladu sa standardnim smjernicama ustanove.
English: Peak levels of anti-CD19 CAR T cells occurred within the first 8 to 15 days after YESCARTA infusion.
Croatian: Vršne razine anti-CD19 CAR T-stanica pojavile su se u prvih 8 do 15 dana nakon infuzije lijeka YESCARTA.
English: Based on the mechanism of action, if the transduced cells cross the placenta, they may cause foetal toxicity, including B-cell lymphocytopenia.
Croatian: Na temelju mehanizma djelovanja, ako transducirane stanice prođu kroz posteljicu, mogu uzrokovati fetalnu toksičnost, uključujući limfocitopeniju B-stanica.
English: The ORR results within PMBCL and DLBCL arising from follicular lymphoma were both 88%.
Croatian: Oba rezultata ORR-a unutar skupine s PMBCL-om i DLBCL-om nastalim iz folikularnog limfoma iznosila su 88%.
English: Thawed product should not be refrozen.
Croatian: Odmrznuti lijek ne smije se ponovno zamrzavati.
English: YESCARTA bags must be stored in the vapour phase of liquid nitrogen (≤ -150 ˚C) and YESCARTA must remain frozen until the patient is ready for treatment to ensure viable live autologous cells are administered to the patient.
Croatian: Vrećice lijeka YESCARTA moraju se čuvati u plinovitoj fazi tekućeg dušika (≤ -150 °C) i lijek YESCARTA mora ostati zamrznut sve dok bolesnik ne bude spreman za infuziju kako bi se osiguralo da će se bolesniku primijeniti vijabilne žive autologne stanice.
English: Serious hypersensitivity reactions including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) or residual gentamicin in YESCARTA.
Croatian: Ozbiljne reakcije preosjetljivosti, uključujući anafilaksiju, mogu se pojaviti zbog dimetilsulfoksida (DMSO) ili preostalog gentamicina u lijeku YESCARTA.
English: Contents: approximately 68 mL of cell dispersion.
Croatian: Sadržaj: približno 68 ml stanične disperzije.
English: Life-threatening symptoms.
Croatian: Simptomi opasni po život.
English: The initiation of B-cell recovery was first noted at Month 9, when 56% of patients had detectable B-cells.
Croatian: Početak oporavka B-stanica prvo je opažen u 9. mjesecu, kad su se B-stanice mogle pronaći u 56% bolesnika.
English: • Look for signs of infection; any infection will be treated before you are given YESCARTA.
Croatian: • provjeriti znakove infekcije; infekcija će se liječiti prije davanja lijeka YESCARTA
English: • Look for signs of graft-versus-host disease that can happen after a transplant.
Croatian: • provjeriti znakove reakcije presatka protiv primatelja koja se može pojaviti nakon transplantacije
English: Patients with a history of CNS disorders such as seizures or cerebrovascular ischaemia may be at increased risk.
Croatian: Bolesnici s povijesti poremećaja središnjeg živčanog sustava, kao što su napadaji ili cerebrovaskularna ishemija, mogu biti pod većim rizikom.
English: Patients who experience Grade 2 or higher neurologic toxicities should be monitored with continuous cardiac telemetry and pulse oximetry.
Croatian: Bolesnike s neurološkim toksičnostima 2. ili višeg stupnja treba pratiti kontinuiranom srčanom telemetrijom i pulsnom oksimetrijom.
English: Symptoms require symptomatic treatment only (e.g., fever, nausea, fatigue, headache, myalgia, malaise).
Croatian: Simptomi zahtijevaju samo simptomatsko liječenje (npr. vrućica, mučnina, umor, glavobolja, mialgija, slabost).
English: Severe CRS, including life-threatening and fatal reactions, was very commonly observed with YESCARTA with a time to onset of 1 to 12 days (see section 4.8).
Croatian: Teški CRS, uključujući opasne po život i smrtonosne reakcije, vrlo je često opažen s lijekom YESCARTA s vremenom pojavljivanja između 1 i 12 dana (vidjeti dio 4.8).
English: Continue corticosteroids use until the event is Grade 1 or less, then taper over 3 days.
Croatian: Nastaviti primjenu kortikosteroida dok se događaj ne ublaži do 1. ili manjeg stupnja, zatim smanjivati tijekom 3 dana.
English: Additional Patient ID: Patient Name:
Croatian: Dodatni ID bolesnika: Ime i prezime bolesnika: Datum rođenja bolesnika:
English: This sequence of events leads to apoptosis and necrosis of CD19-expressing target cells.
Croatian: Taj slijed događaja dovodi do apoptoze i nekroze ciljanih stanica koje izražavaju CD19.
English: Your doctor will recommend that you return to the hospital daily for at least 10 days and will consider whether you need to stay at the hospital as an in-patient for the first 10 days after infusion.
Croatian: Liječnik će Vam preporučiti da dolazite u bolnicu svakog dana još najmanje 10 dana i odlučit će hoće li biti potrebno da ostanete u bolnici prvih 10 dana nakon infuzije, kako bi mogao provjeravati je li Vam liječenje djelotvorno i pomoći u slučaju nuspojava.
English: For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function.
Croatian: U bolesnika s teškim CRS-om razmislite o provedbi ehokardiograma za procjenu srčane funkcije.
English: The MAH shall ensure that in each Member State where YESCARTA is marketed, all HCPs who are expected to prescribe, dispense, and administer YESCARTA shall be provided with a guidance document to: - facilitate identification of CRS and serious neurologic adverse reactions - facilitate management of the CRS and serious neurologic adverse reactions - ensure adequate monitoring of CRS and serious neurologic adverse reactions - facilitate provision of all relevant information to patients - ensure that adverse reactions are adequately and appropriately reported - ensure that detailed instructions about the thawing procedure are provided - before treating a patient, ensure that 4 doses of tocilizumab for each patient are available on site
Croatian: Nositelj odobrenja mora osigurati da u svakoj državi članici u kojoj je lijek YESCARTA stavljen u promet svi zdravstveni radnici za koje se očekuje da će propisivati, izdavati i primjenjivati lijek YESCARTA dobiju dokument sa smjernicama kako bi se: olakšalo prepoznavanje CRS-a i ozbiljnih neuroloških nuspojava olakšalo liječenje CRS-a i ozbiljnih neuroloških nuspojava osiguralo odgovarajuće praćenje CRS-a i ozbiljnih neuroloških nuspojava olakšalo davanje svih važnih informacija bolesnicima osiguralo odgovarajuće i primjereno izvješćivanje o nuspojavama osiguralo davanje detaljnih uputa za postupak odmrzavanja osiguralo da su u bolničkoj ustanovi za svakog bolesnika dostupne 4 doze tocilizumaba prije liječenja.
English: Excipients: Cryostor CS10, human albumin, sodium chloride.
Croatian: Pomoćne tvari: Cryostor CS10, ljudski albumin, natrijev klorid.
English: Muscular weakness and leukoencephalopathy are listed in the axicabtagene ciloleucel product information.
Croatian: Mišićna slabost i leukoencefalopatija navedene su u informacijama o lijeku za aksikaptagen ciloleucel.
English: • YESCARTA is the genetically modified version of your white blood cells.
Croatian: • YESCARTA je genetički modificirana verzija Vaših leukocita.
English: YESCARTA should not be administered to patients with active infections or inflammatory disease until these conditions have resolved.
Croatian: Lijek YESCARTA ne smije se primjenjivati u bolesnika s aktivnim infekcijama ili upalnim bolestima dok se navedena stanja ne povuku.
English: Patients must have received at least prior anti-CD20 antibody therapy and an anthracycline containing regimen.
Croatian: Bolesnici su prethodno morali primiti barem terapiju protutijelom anti-CD20 i režim koji sadrži antraciklin.
English: • Thaw YESCARTA at approximately 37 °C using either a water bath or dry thaw method until there is no visible ice in the infusion bag.
Croatian: • Lijek YESCARTA odmrznite na temperaturi od približno 37 °C pomoću vodene kupelji ili metode suhog odmrzavanja dok ne iščeznu znakovi leda unutar vrećice s infuzijom.
English: Of the 111 patients in the ITT population, the ORR was 66% and the CR was 47%.
Croatian: Rezultat ORR-a za 111 bolesnika u populaciji planiranoj za liječenje iznosio je 66%, dok je CR iznosio 47%.
English: This is to help prevent infusion reactions and fever.
Croatian: Time se sprječavaju reakcije na infuziju i vrućica.
English: If any of the above apply to you (or you are not sure), talk to your doctor before being given YESCARTA.
Croatian: Ako se bilo što od prethodno navedenoga odnosi na Vas (ili ako niste sigurni), obratite se svom liječniku ili medicinskoj sestri prije nego što primite lijek YESCARTA.
English: Serious adverse reactions that may be associated with CRS included acute kidney injury, atrial fibrillation, ventricular tachycardia, cardiac arrest, cardiac failure, capillary leak syndrome, hypotension, hypoxia, and HLH/MAS.
Croatian: Ozbiljne nuspojave koje mogu biti povezane s CRS-om uključivale su akutno oštećenje bubrega, fibrilaciju atrija, ventrikularnu tahikardiju, srčani zastoj, zatajenje srca, sindrom povećane propusnosti kapilara, hipotenziju, hipoksiju i HLH/MAS.
English: Work surfaces and material which have potentially been in contact with YESCARTA must be decontaminated with appropriate disinfectant.
Croatian: Radne površine i materijal za koje postoji mogućnost da su bili u kontaktu s lijekom YESCARTA moraju se dekontaminirati primjenom odgovarajućeg dezinfekcijskog sredstva.
English: Duration of Responsea, median (range) in months
Croatian: Trajanje odgovoraa, medijan (raspon) u mjesecima
English: This medicinal product contains 300 mg sodium per infusion, equivalent to 15% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Croatian: Ovaj lijek sadrži 300 mg natrija po infuziji, što odgovara 15% maksimalnog dnevnog unosa od 2 g natrija prema preporukama Svjetske zdravstvene organizacije za odraslu osobu.
English: YESCARTA can cause side effects to your immune system that may be serious or life-threatening, and can lead to death.
Croatian: Lijek YESCARTA može uzrokovati nuspojave Vašem imunosnom sustavu koje mogu biti ozbiljne ili opasne po život te mogu dovesti do smrti.
English: Do not use this medicine after the expiry date which is stated on the container label and infusion bag.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici na spremniku i vrećici za infuziju.
English: Tumour lysis syndrome (TLS)
Croatian: Sindrom tumorske lize (STL)
English: The other ingredients (excipients) are: Cryostor CS10, sodium chloride, human albumin.
Croatian: Drugi sastojci (pomoćne tvari) su: Cryostor CS10, natrijev klorid, ljudski albumin.
English: Bridging chemotherapy between leukapheresis and lymphodepleting chemotherapy was not permitted.
Croatian: Prijelazna kemoterapija između leukafereze i kemoterapije za limfocitnu depleciju nije bila dopuštena.
English: Grade 3 or higher (severe, life-threatening, or fatal) infections occurred in 26% of patients.
Croatian: Infekcije 3. ili višeg stupnja (teške, opasne po život ili smrtonosne) imalo je 26% bolesnika.
English: Patients with a history of CNS disorders (such as seizures or cerebrovascular ischemia), cardiac ejection fraction of less than 50% or room air oxygen saturation of less than 92%, or autoimmune disease requiring systemic immunosuppression were ineligible.
Croatian: Bolesnici s povijesti poremećaja središnjeg živčanog sustava (kao što su napadaji ili cerebrovaskularna ishemija), srčanom istisnom frakcijom manjom od 50% ili zasićenosti kisikom manjom od 92% na sobnom zraku ili autoimunom bolesti koja zahtijeva sistemsku imunosupresiju nisu bili podobni.
English: For special precautions for disposal, see section 6.6.
Croatian: Posebne mjere za zbrinjavanje vidjeti u dijelu 6.6.
English: Pre-treatment (lymphodepleting chemotherapy)
Croatian: Prije liječenja (kemoterapija za limfocitnu depleciju)
English: Requirements for ventilator support or continuous veno-venous haemodialysis or Grade 4 organ toxicity (excluding transaminitis).
Croatian: Potrebna ventilacijska potpora ili kontinuirana venovenska hemodijaliza ili toksično oštećenje organa 4. stupnja (osim transaminitisa).
English: Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during YESCARTA treatment, and until immune recovery following treatment with YESCARTA.
Croatian: Cijepljenje cjepivima koja sadrže žive viruse ne preporučuje se najmanje 6 tjedana prije početka limfocitne deplecije, tijekom terapije lijekom YESCARTA i do oporavka imuniteta nakon terapije lijekom YESCARTA.
English: The anti-CD19 CAR-positive viable T cells are expanded and infused back into the patient, where they can recognise and eliminate CD19-expressing target cells.
Croatian: Anti-CD19 CAR-pozitivne vijabilne T-stanice se zatim umnažaju i infundiraju u bolesnika, gdje mogu prepoznati i eliminirati ciljne stanice koje eksprimiraju CD19.
English: Concurrent CRS
Croatian: Istodobni CRS
English: Only cytopenias that resulted in (i) new or worsening clinical sequelae or (ii) that required therapy or (iii) adjustment in current therapy are included in Table 3.
Croatian: U tablicu 3 uključene su samo citopenije koje su rezultirale (i) novim kliničkim sekvelama ili pogoršanjem postojećih ili (ii) koje su zahtijevale terapiju ili (iii) prilagodbu postojeće terapije.
English: If you miss any appointments, call your doctor or the qualified clinical facility as soon as possible to reschedule your appointment.
Croatian: Ako propustite zakazani dolazak na terapiju, nazovite liječnika ili specijaliziranu bolničku ustanovu što prije i dogovorite novi dolazak.
English: • Since YESCARTA is made from your own white blood cells, your cells will be collected from you to prepare your medicine.
Croatian: • Budući da je lijek YESCARTA izrađen od Vaših leukocita, od Vas će se prikupiti krvne stanice za pripremu lijeka.
English: • In the 6 weeks before you are given the short course of chemotherapy (called lymphodepleting chemotherapy) to prepare your body for the YESCARTA cells.
Croatian: • unutar 6 tjedana prije primanja kratke kemoterapije (ona se naziva kemoterapija za limfocitnu depleciju) kojom će se Vaše tijelo pripremiti za stanice lijeka YESCARTA
English: Prior to receiving YESCARTA, you will be given other medicines such as preparative chemotherapy, which will allow your modified white blood cells in YESCARTA to multiply in your body when the medicine is given to you.
Croatian: Prije nego što primite lijek YESCARTA primit ćete druge lijekove kao što je pripremna kemoterapija, što će omogućiti umnažanje Vaših modificiranih leukocita iz lijeka YESCARTA u Vašem organizmu nakon što primite lijek.
English: Patients should be monitored for signs and symptoms of infection before, during, and after YESCARTA infusion and treated appropriately.
Croatian: Bolesnike je potrebno pratiti zbog moguće pojave znakova i simptoma infekcije prije, tijekom i nakon infuzije lijeka YESCARTA te liječiti na odgovarajući način.
English: YESCARTA 0.4 - 2 x 108 cells dispersion for infusion
Croatian: YESCARTA 0,4 - 2 x 108 stanica disperzija za infuziju
English: No carcinogenicity or genotoxicity studies have been conducted with YESCARTA.
Croatian: Nisu provedena ispitivanja karcinogenosti ili genotoksičnosti s lijekom YESCARTA.
English: • Check your blood for uric acid and for how many cancer cells there are in your blood.
Croatian: • provjeriti koncentraciju mokraćne kiseline i broj stanica raka u krvi.
English: A causal relationship between spinal cord lesions and axicabtagene ciloleucel was confirmed, based on the evidence from two clinical trial cases; one case with an event of quadriplegia (in the setting of myelitis) and second case with events of muscular weakness and leukoencephalopathy, and one spontaneous case report with an event of spinal cord oedema.
Croatian: Uzročno-posljedična veza između lezija leđne moždine i aksikaptagen ciloleucela potvrđena je na temelju dokaza iz dva slučaja u kliničkom ispitivanju; jedan se slučaj odnosio na događaj kvadriplegije (kod mijelitisa), a drugi slučaj na događaje mišićne slabosti i leukoencefalopatije, i jedne spontane prijave slučaja koji se odnosio na događaj edema leđne moždine.
English: On the basis of the scientific conclusions for axicabtagene ciloleucel the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing axicabtagene ciloleucel is unchanged subject to the proposed changes to the product information
Croatian: Na temelju znanstvenih zaključaka za aksikaptagen ciloleucel, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) aksikaptagen ciloleucel nepromijenjen, uz predložene izmjene informacija o lijeku.
English: Among 73 patients with evaluable samples at baseline, 40% had detectable B-cells; the B-cell aplasia observed in the majority of patients at baseline was attributed to prior therapies.
Croatian: Među 73 ispitanika s procjenjivim uzorcima na početku ispitivanja, postojanje B-stanica moglo se ustanoviti u njih 40%; aplazija B-stanica opažena u većine bolesnika na početku ispitivanja bila je pripisana prethodnoj terapiji.
English: Your doctor may do blood tests to check for side effects.
Croatian: Liječnik Vam može napraviti krvne pretrage kako bi provjerio postoje li nuspojave.
English: During the 30 to 60 minutes before you are given YESCARTA you may be given other medicines.
Croatian: Lijekovi koje ćete primiti prije liječenja lijekom YESCARTA Otprilike 30 do 60 minuta prije nego što primite lijek YESCARTA možda ćete primiti druge lijekove.
English: Fatal and serious cases of cerebral oedema have been reported in patients treated with YESCARTA.
Croatian: Prijavljeni su ozbiljni i smrtonosni slučajevi cerebralnog edema u bolesnika liječenih lijekom YESCARTA.
English: YESCARTA must not be irradiated.
Croatian: Lijek YESCARTA ne smije se izlagati zračenju.
English: A single infusion bag contains approximately 68 mL of cell dispersion.
Croatian: Jedna vrećica za infuziju sadrži približno 68 ml stanične disperzije.
English: A causal relationship between dysphagia and axicabtagene ciloleucel was confirmed, based on the evidence from 15 post-marketing cases and 4 clinical trial cases of dysphagia.
Croatian: Uzročno-posljedična veza između disfagije i aksikaptagen ciloleucela potvrđena je na temelju dokaza iz 15 slučajeva nakon stavljanja lijeka u promet i 4 slučaja disfagije u kliničkom ispitivanju.
English: Administer tocilizumab per Table 1 for management of Grade 2 CRS.
Croatian: Primijeniti tocilizumab prema liječenju CRS-a 2. stupnja u tablici 1.
English: Physicians should consider hospitalisation for the first 10 days post infusion or at the first signs or symptoms of CRS and/or neurologic events.
Croatian: Liječnici trebaju razmotriti potrebu za hospitalizacijom tijekom prvih 10 dana nakon infuzije ili pri pojavi prvih znakova ili simptoma CRS-a i/ili neuroloških događaja.
English: Serious infections have been very commonly observed with YESCARTA (see section 4.8).
Croatian: Ozbiljne infekcije vrlo su često opažene s lijekom YESCARTA (vidjeti dio 4.8).
English: The median dose was 2.0 x 106 anti-CD19 CAR T cells/kg.
Croatian: Medijan doze iznosio je 2,0 x 106 anti-CD19 CAR T-stanica/kg.
English: The median time from leukapheresis to product delivery was 17 days (range: 14 to 51 days), and the median time from leukapheresis to infusion was 24 days (range: 16 to 73 days).
Croatian: Medijan vremena od leukafereze do dostave lijeka bio je 17 dana (raspon: od 14 do 51 dan) dok je medijan vremena od leukafereze do infuzije bio 24 dana (raspon: od 16 do 73 dana).
English: The anticipated metabolic products are typical cellular degradation products resulting from normal cellular clearance mechanisms.
Croatian: Očekivani metabolički produkti uobičajeni su produkti raspada stanica koji su rezultat prirodnih mehanizama uklanjanja raspadnih tvari iz stanica.
English: Unresolved serious adverse reactions (especially pulmonary reactions, cardiac reactions, or hypotension) including from preceding chemotherapies.
Croatian: • neriješene ozbiljne nuspojave (osobito plućne reakcije, srčane reakcije ili hipotenziju),
English: • Chills, extreme tiredness, weakness, dizziness, headache, cough, shortness of breath, or rapid heartbeat, which may be symptoms of a condition known as cytokine release syndrome.
Croatian: • zimice, prevelik umor, slabost, omaglicu, glavobolju, kašalj, nedostatak zraka ili ubrzano kucanje srca, što mogu biti simptomi stanja koje se naziva sindrom otpuštanja citokina.
English: Other neurologic adverse reactions have been reported less frequently in clinical trials and included dysphagia (5%), myelitis (0.2%), and quadriplegia (0.2%).
Croatian: Druge neurološke nuspojave zabilježene su u kliničkim ispitivanjima s manjom učestalosti, a uključivale su disfagiju (5%), mijelitis (0,2%) i kvadriplegiju (0,2%).
English: The active substance is axicabtagene ciloleucel.
Croatian: Djelatna tvar je aksikaptagen ciloleucel.
English: Continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days.
Croatian: Nastaviti primjenu deksametazona dok se događaj ne ublaži do 1. ili manjeg stupnja, a zatim smanjivati tijekom 3 dana.
English: Efficacy was based on 101 patients in phase 2, including histologically confirmed DLBCL (N = 77), PMBCL (N = 8), or DLBCL arising from follicular lymphoma, (N = 16) based on the 2008 WHO-classification.
Croatian: Djelotvornost se temeljila na podacima za 101 bolesnika u fazi 2, uključujući histološki potvrđen DLBCL (N = 77), PMBCL (N = 8) ili DLBCL nastao iz folikularnog limfoma (N = 16), prema klasifikaciji Svjetske zdravstvene organizacije iz 2008. godine.
English: The DOR was longer in patients who achieved CR compared to patients with a best response of PR (Table 5).
Croatian: DOR je bio dulji u bolesnika koji su postigli CR u usporedbi s bolesnicima kojima je najbolji odgovor bio PR (tablica 5).
English: In addition, administer dexamethasone 10 mg intravenously with the first dose of tocilizumab and repeat dose every 6 hours.
Croatian: Uz to, potrebno je intravenski primijeniti 10 mg deksametazona s prvom dozom tocilizumaba i ponoviti dozu svakih 6 sati.
English: The most significant and frequently occurring adverse reactions were CRS (93%), encephalopathy (58%), and infections (39%).
Croatian: Najznačajnije i najčešće nuspojave bile su CRS (93%), encefalopatija (58%) i infekcije (39%).
English: The median duration of follow up was 27.4 months.
Croatian: Medijan trajanja praćenja iznosio je 27,4 mjeseca.
English: • Patients should be monitored daily for the first 10 days following infusion for signs and symptoms of potential CRS, neurologic events and other toxicities.
Croatian: • Bolesnike treba svakodnevno pratiti prvih 10 dana nakon infuzije zbog pojave znakova i simptoma mogućeg CRS-a, neuroloških događaja i drugih toksičnosti.
English: In the 12-month follow-up analysis (Table 5), the ORR was 72% and the CR rate was 51%.
Croatian: U analizi podataka nakon 12 mjeseci praćenja (tablica 5) ORR je bio 72%, a stopa CR-a 51%.
English: All material that has been in contact with YESCARTA (solid and liquid waste) should be handled and disposed of as potentially infectious waste in accordance with local biosafety guidelines.
Croatian: Svim materijalima koji su bili u kontaktu s lijekom YESCARTA (kruti i tekući otpad) treba rukovati i zbrinuti ga kao potencijalno zarazan otpad u skladu s nacionalnim smjernicama za biološku sigurnost.